(5-氨基-2,3-二甲氧基苯基)甲醇 | 1111236-54-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (5-氨基-2,3-二甲氧基苯基)甲醇
• 英文名称: (5-Amino-2,3-dimethoxyphenyl)methanol
• CAS: 1111236-54-4
• 化学式: C₉H₁₃NO₃
• mdl: MFCD11520373
• 分子量: 183.207
• InChiKey: WIRKQQHDZDLBAT-UHFFFAOYSA-N

物化性质

• 沸点：
  346℃
• 密度：
  1.193
• 闪点：
  163℃

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  64.7
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2922509090

反应信息

• 作为反应物：
  描述：

  (5-氨基-2,3-二甲氧基苯基)甲醇 在 对甲苯磺酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 40.0h， 生成 [2,3-Dimethoxy-5-[[4-[2-[methyl-[2-(methylamino)ethyl]amino]pyridin-4-yl]pyrimidin-2-yl]amino]phenyl]methanol
  参考文献：
  名称：

  [EN] 4-ARYL-2-ANILINO-PYRIMIDINES AS PLK KINASE INHIBITORS
  [FR] 4-ARYL-2-ANILINO-PYRIMIDINES COMME INHIBITEURS DE PLK KINASES

  摘要：

  本发明涉及式(Ia)或(Ib)的化合物，其N-氧化物形式，药学上可接受的加盐物，季铵盐，立体异构体，互变异构体，消旋体，代谢物，前药，水合物或其溶剂化合物，其中Y1，m，n，R1；X1；X2；R2；X3；X4；R3；和R4在权利要求中定义的含义。本发明还涉及制备所述化合物的方法，含有它们的药物组合物以及它们在治疗中的用途。该发明特别涉及激酶抑制剂，用于治疗由激酶介导的疾病状态，特别是PLK4，特别是对治疗涉及异常细胞增殖的病理过程有用的化合物，如肿瘤生长、类风湿关节炎、再狭窄和动脉粥样硬化。

  公开号：

  WO2009112439A1
• 作为产物：
  描述：

  2,3-dimethoxy-5-nitro-benzyl alcohol 在 platinum on carbon 氢气 作用下， 以 噻吩 、 甲醇 、 异丙醚 为溶剂， 反应 20.0h， 以80%的产率得到(5-氨基-2,3-二甲氧基苯基)甲醇
  参考文献：
  名称：

  [EN] 4-ARYL-2-ANILINO-PYRIMIDINES AS PLK KINASE INHIBITORS
  [FR] 4-ARYL-2-ANILINO-PYRIMIDINES COMME INHIBITEURS DE PLK KINASES

  摘要：

  本发明涉及式(Ia)或(Ib)的化合物，其N-氧化物形式，药学上可接受的加盐物，季铵盐，立体异构体，互变异构体，消旋体，代谢物，前药，水合物或其溶剂化合物，其中Y1，m，n，R1；X1；X2；R2；X3；X4；R3；和R4在权利要求中定义的含义。本发明还涉及制备所述化合物的方法，含有它们的药物组合物以及它们在治疗中的用途。该发明特别涉及激酶抑制剂，用于治疗由激酶介导的疾病状态，特别是PLK4，特别是对治疗涉及异常细胞增殖的病理过程有用的化合物，如肿瘤生长、类风湿关节炎、再狭窄和动脉粥样硬化。

  公开号：

  WO2009112439A1

文献信息

• COMBRETASTATIN DERIVATIVES AND USES THEREFOR
  申请人：Meegan Mary J.

  公开号：US20120309734A1

  公开（公告）日：2012-12-06

  Cancer is one of the major causes of death worldwide. Although many advances have been made in the treatment and management of the disease, the existence of chemotherapy-resistance means there is still a great need to develop new strategies and drugs for its treatment. Provided herein are synthetic derivatives of combretastatin A-4, in particular those in which the aromatic rings are locked into a non-isomerisable active conformation, thus resulting in improved, stable compounds. The novel compounds are structurally related to combretastatin A-4 (CA-4) and lock the rings into the known active conformation by means of a four membered nitrogen containing heterocyclic ring, such as a beta-lactam ring, incorporated into the standard CA-4 structure. The compounds exhibit potent anti-cancer activity.

  癌症是全球主要的死因之一。尽管在治疗和管理该疾病方面取得了许多进展，但化疗耐药的存在意味着仍然需要开发新的策略和药物来治疗癌症。本文提供了合成的血树碱A-4的衍生物，特别是那些将芳香环锁定在非可异构的活性构象中，从而产生改进的、稳定的化合物。这些新型化合物与血树碱A-4（CA-4）有结构上的关联，并通过一种四元杂环环（例如β-内酰胺环）将环锁定在已知的活性构象中。这些化合物表现出强大的抗癌活性。
• PYRROLOPYRIMIDINES
  申请人：Diels Gaston Stanislas Marcella

  公开号：US20100204197A1

  公开（公告）日：2010-08-12

  The present invention relates to compounds or pharmaceutically-acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to compounds that are polo-like kinase (PLKs) inhibitors useful for the treatment of disease states mediated by PLK, especially PLK4, in particular such compounds that are useful in the treatment of pathological processes which involve an aberrant cellular proliferation, such as tumour growth, rheumatoid arthritis, restenosis and atherosclerosis.
• 4-ARYL-2-ANILINO-PYRIMIDINES
  申请人：Buijnsters Peter Jacobus Johannes

  公开号：US20110009404A1

  公开（公告）日：2011-01-13

  The present invention relates to compounds of Formula (Ia) or (Ib), the N-oxide forms, pharmaceutically acceptable addition salts, quaternary amines, stereoisomers, tautomers, racemics, metabolites, prodrugs, hydrates, or solvates thereof, wherein Y 1 , m, n, R 1 ; X 1 ; X 2 ; R 2 ; X 3 ; X 4 ; R 3 ; and R 4 have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to compounds that are kinase inhibitors useful for the treatment of disease states mediated by kinase, especially PLK4, in particular such compounds that are useful in the treatment of pathological processes which involve an aberrant cellular proliferation, such as tumor growth, rheumatoid arthritis, restenosis and atherosclerosis.
• FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC
  申请人：Burns Barbier Lindsay

  公开号：US20110105484A1

  公开（公告）日：2011-05-05

  A compound, its pharmaceutically acceptable salt, a composition containing the same and method of treatment that can provide analgesia and/or reduce inflammation are disclosed. A contemplated compound has a structure that corresponds to Formula A, wherein G, W, Q, Z, D, E, F, K, Y, d, e, f, k, n, m, and circle B and all R groups are defined within.
• FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC
  申请人：Burns Barbier Lindsay

  公开号：US20110105481A1

  公开（公告）日：2011-05-05

  A compound or its pharmaceutically acceptable salt, optionally including both individual enantiomeric forms, a racemate, diastereomers and mixtures thereof, composition and method are disclosed that can provide analgesia and reduce inflammation. A contemplated compound has a structure that corresponds to Formula A, wherein the R group substituents, d, e, f, k, n, m, D, E, F, K, G, P, Q, W, and Z are defined within.